ICSMA-20-170-05
Vulnerability from csaf_cisa - Published: 2020-06-18 00:00 - Updated: 2020-06-18 00:00Summary
BIOTRONIK CardioMessenger II
Notes
CISA Disclaimer
This CSAF advisory was extracted from unstructured data and may contain inaccuracies. If you notice any errors, please reach out to the designated contact at CISA CSAF: central@cisa.dhs.gov
Legal Notice
All information products included in https://us-cert.cisa.gov/ics are provided "as is" for informational purposes only. The Department of Homeland Security (DHS) does not provide any warranties of any kind regarding any information contained within. DHS does not endorse any commercial product or service, referenced in this product or otherwise. Further dissemination of this product is governed by the Traffic Light Protocol (TLP) marking in the header. For more information about TLP, see https://us-cert.cisa.gov/tlp/.
Risk evaluation
Successful exploitation of these vulnerabilities could allow an attacker with physical access to the CardioMessenger to obtain sensitive data, obtain transmitted medical data from implanted cardiac devices with the implant 's serial number or impact Cardio Messenger II product functionality. Successful exploitation of these vulnerabilities could allow an attacker with adjacent access to influence communications between the Home Monitoring Unit (HMU) and the Access Point Name (APN) gateway network.
Critical infrastructure sectors
Healthcare and Public Health
Countries/areas deployed
Worldwide
Company headquarters location
Germany
Recommended Practices
CISA recommends users take defensive measures to minimize the risk of exploitation of this vulnerability. Specifically, users should:
Recommended Practices
CISA reminds organizations to perform proper impact analysis and risk assessment prior to deploying defensive measures.
CISA also provides a section for control systems security recommended practices on the ICS webpage onus-cert.gov. Several recommended practices are available for reading and download, including Improving Industrial Control Systems Cybersecurity with Defense-in-Depth Strategies.
Recommended Practices
Additional mitigation guidance and recommended practices are publicly available on the ICS webpage on us-cert.gov in the Technical Information Paper, ICS-TIP-12-146-01B--Targeted Cyber Intrusion Detection and Mitigation Strategies.
Organizations observing any suspected malicious activity should follow their established internal procedures and report their findings to CISA for tracking and correlation against other incidents.
Exploitability
No known public exploits specifically target these vulnerabilities.
{
"document": {
"acknowledgments": [
{
"names": [
"Guillaume Bour",
"Anniken Wium Lie",
"Marie Moe"
],
"summary": "reporting these vulnerabilities to CISA"
}
],
"category": "csaf_security_advisory",
"csaf_version": "2.0",
"distribution": {
"text": "Disclosure is not limited",
"tlp": {
"label": "WHITE",
"url": "https://us-cert.cisa.gov/tlp/"
}
},
"lang": "en-US",
"notes": [
{
"category": "general",
"text": "This CSAF advisory was extracted from unstructured data and may contain inaccuracies. If you notice any errors, please reach out to the designated contact at CISA CSAF: central@cisa.dhs.gov",
"title": "CISA Disclaimer"
},
{
"category": "legal_disclaimer",
"text": "All information products included in https://us-cert.cisa.gov/ics are provided \"as is\" for informational purposes only. The Department of Homeland Security (DHS) does not provide any warranties of any kind regarding any information contained within. DHS does not endorse any commercial product or service, referenced in this product or otherwise. Further dissemination of this product is governed by the Traffic Light Protocol (TLP) marking in the header. For more information about TLP, see https://us-cert.cisa.gov/tlp/.",
"title": "Legal Notice"
},
{
"category": "summary",
"text": "Successful exploitation of these vulnerabilities could allow an attacker with physical access to the CardioMessenger to obtain sensitive data, obtain transmitted medical data from implanted cardiac devices with the implant \u0027s serial number or impact Cardio Messenger II product functionality. Successful exploitation of these vulnerabilities could allow an attacker with adjacent access to influence communications between the Home Monitoring Unit (HMU) and the Access Point Name (APN) gateway network.",
"title": "Risk evaluation"
},
{
"category": "other",
"text": "Healthcare and Public Health",
"title": "Critical infrastructure sectors"
},
{
"category": "other",
"text": "Worldwide",
"title": "Countries/areas deployed"
},
{
"category": "other",
"text": "Germany",
"title": "Company headquarters location"
},
{
"category": "general",
"text": "CISA recommends users take defensive measures to minimize the risk of exploitation of this vulnerability. Specifically, users should:",
"title": "Recommended Practices"
},
{
"category": "general",
"text": "CISA reminds organizations to perform proper impact analysis and risk assessment prior to deploying defensive measures.\nCISA also provides a section for control systems security recommended practices on the ICS webpage onus-cert.gov. Several recommended practices are available for reading and download, including Improving Industrial Control Systems Cybersecurity with Defense-in-Depth Strategies.",
"title": "Recommended Practices"
},
{
"category": "general",
"text": "Additional mitigation guidance and recommended practices are publicly available on the ICS webpage on us-cert.gov in the Technical Information Paper, ICS-TIP-12-146-01B--Targeted Cyber Intrusion Detection and Mitigation Strategies.\nOrganizations observing any suspected malicious activity should follow their established internal procedures and report their findings to CISA for tracking and correlation against other incidents.",
"title": "Recommended Practices"
},
{
"category": "other",
"text": "No known public exploits specifically target these vulnerabilities.",
"title": "Exploitability"
}
],
"publisher": {
"category": "coordinator",
"contact_details": "Email: CISAservicedesk@cisa.dhs.gov;\n Toll Free: 1-888-282-0870",
"name": "CISA",
"namespace": "https://www.cisa.gov/"
},
"references": [
{
"category": "self",
"summary": "ICS Advisory ICSMA-20-170-05 JSON",
"url": "https://raw.githubusercontent.com/cisagov/CSAF/develop/csaf_files/OT/white/2020/icsma-20-170-05.json"
},
{
"category": "self",
"summary": "ICS Advisory ICSMA-20-170-05 Web Version",
"url": "https://www.cisa.gov/news-events/ics-medical-advisories/icsma-20-170-05"
},
{
"category": "external",
"summary": "Recommended Practices",
"url": "https://www.fda.gov/medical-devices/digital-health/cybersecurity"
},
{
"category": "external",
"summary": "Recommended Practices",
"url": "https://www.us-cert.gov/sites/default/files/recommended_practices/NCCIC_ICS-CERT_Defense_in_Depth_2016_S508C.pdf"
},
{
"category": "external",
"summary": "Recommended Practices",
"url": "https://www.us-cert.gov/ics/tips/ICS-TIP-12-146-01B"
}
],
"title": "BIOTRONIK CardioMessenger II",
"tracking": {
"current_release_date": "2020-06-18T00:00:00.000000Z",
"generator": {
"engine": {
"name": "CISA CSAF Generator",
"version": "1.0.0"
}
},
"id": "ICSMA-20-170-05",
"initial_release_date": "2020-06-18T00:00:00.000000Z",
"revision_history": [
{
"date": "2020-06-18T00:00:00.000000Z",
"legacy_version": "Initial",
"number": "1",
"summary": "ICSMA-20-170-05 BIOTRONIK Cardio Messenger II"
}
],
"status": "final",
"version": "1"
}
},
"product_tree": {
"branches": [
{
"branches": [
{
"branches": [
{
"category": "product_version",
"name": "2.2",
"product": {
"name": "CardioMessenger II-S T-Line T4APP: 2.20",
"product_id": "CSAFPID-0001"
}
}
],
"category": "product_name",
"name": "CardioMessenger II-S T-Line T4APP"
},
{
"branches": [
{
"category": "product_version",
"name": "2.2",
"product": {
"name": "CardioMessenger II-S GSM T4APP: 2.20",
"product_id": "CSAFPID-0002"
}
}
],
"category": "product_name",
"name": "CardioMessenger II-S GSM T4APP"
}
],
"category": "vendor",
"name": "BIOTRONIK"
}
]
},
"vulnerabilities": [
{
"cve": "CVE-2019-18246",
"cwe": {
"id": "CWE-287",
"name": "Improper Authentication"
},
"notes": [
{
"category": "summary",
"text": "The affected products do not properly enforce mutual authentication with the BIOTRONIK Remote Communication infrastructure. CVE-2019-18246 has been assigned to this vulnerability. A CVSS v3 base score of 4.3 has been calculated; the CVSS vector string is (AV:A/AC:L/PR:N/UI:N/S:U/C:L/I:N/A:N).",
"title": "Vulnerability Summary"
}
],
"product_status": {
"known_affected": [
"CSAFPID-0001",
"CSAFPID-0002"
]
},
"references": [
{
"category": "external",
"summary": "web.nvd.nist.gov",
"url": "http://web.nvd.nist.gov/view/vuln/detail?vulnId=CVE-2019-18246"
},
{
"category": "external",
"summary": "www.first.org",
"url": "https://www.first.org/cvss/calculator/3.0#CVSS:3.0/AV:A/AC:L/PR:N/UI:N/S:U/C:L/I:N/A:N"
}
],
"remediations": [
{
"category": "vendor_fix",
"details": "BIOTRONIK reports they will not be issuing a product security update; however, BIOTRONIK has identified compensating controls which have been put place that reduce the risk of exploitation and prevent patient safety risks. BIOTRONIK assessed these vulnerabilities and determined no new potential safety risks exist.\nBIOTRONIK recommends users take the following defensive measures to minimize the risk of exploitation of these vulnerabilities. Specifically, users should:",
"product_ids": [
"CSAFPID-0001",
"CSAFPID-0002"
]
}
],
"scores": [
{
"cvss_v3": {
"baseScore": 4.3,
"baseSeverity": "MEDIUM",
"vectorString": "CVSS:3.0/AV:A/AC:L/PR:N/UI:N/S:U/C:L/I:N/A:N",
"version": "3.0"
},
"products": [
"CSAFPID-0001",
"CSAFPID-0002"
]
}
]
},
{
"cve": "CVE-2019-18248",
"cwe": {
"id": "CWE-319",
"name": "Cleartext Transmission of Sensitive Information"
},
"notes": [
{
"category": "summary",
"text": "The affected products transmit credentials in cleartext prior to switching to an encrypted communication channel. An attacker can disclose the product \u0027s client credentials for connecting to the BIOTRONIK Remote Communication infrastructure.CVE-2019-18248 has been assigned to this vulnerability. A CVSS v3 base score of 4.3 has been calculated; the CVSS vector string is (AV:A/AC:L/PR:N/UI:N/S:U/C:L/I:N/A:N).",
"title": "Vulnerability Summary"
}
],
"product_status": {
"known_affected": [
"CSAFPID-0001",
"CSAFPID-0002"
]
},
"references": [
{
"category": "external",
"summary": "web.nvd.nist.gov",
"url": "http://web.nvd.nist.gov/view/vuln/detail?vulnId=CVE-2019-18248"
},
{
"category": "external",
"summary": "www.first.org",
"url": "https://www.first.org/cvss/calculator/3.0#CVSS:3.0/AV:A/AC:L/PR:N/UI:N/S:U/C:L/I:N/A:N"
}
],
"remediations": [
{
"category": "vendor_fix",
"details": "BIOTRONIK reports they will not be issuing a product security update; however, BIOTRONIK has identified compensating controls which have been put place that reduce the risk of exploitation and prevent patient safety risks. BIOTRONIK assessed these vulnerabilities and determined no new potential safety risks exist.\nBIOTRONIK recommends users take the following defensive measures to minimize the risk of exploitation of these vulnerabilities. Specifically, users should:",
"product_ids": [
"CSAFPID-0001",
"CSAFPID-0002"
]
}
],
"scores": [
{
"cvss_v3": {
"baseScore": 4.3,
"baseSeverity": "MEDIUM",
"vectorString": "CVSS:3.0/AV:A/AC:L/PR:N/UI:N/S:U/C:L/I:N/A:N",
"version": "3.0"
},
"products": [
"CSAFPID-0001",
"CSAFPID-0002"
]
}
]
},
{
"cve": "CVE-2019-18252",
"cwe": {
"id": "CWE-287",
"name": "Improper Authentication"
},
"notes": [
{
"category": "summary",
"text": "The affected products allow credential reuse for multiple authentication purposes. An attacker with adjacent access to the CardioMessenger can disclose its credentials used for connecting to the BIOTRONIK Remote Communication infrastructure.CVE-2019-18252 has been assigned to this vulnerability. A CVSS v3 base score of 4.3 has been calculated; the CVSS vector string is (AV:A/AC:L/PR:N/UI:N/S:U/C:L/I:N/A:N).",
"title": "Vulnerability Summary"
}
],
"product_status": {
"known_affected": [
"CSAFPID-0001",
"CSAFPID-0002"
]
},
"references": [
{
"category": "external",
"summary": "web.nvd.nist.gov",
"url": "http://web.nvd.nist.gov/view/vuln/detail?vulnId=CVE-2019-18252"
},
{
"category": "external",
"summary": "www.first.org",
"url": "https://www.first.org/cvss/calculator/3.0#CVSS:3.0/AV:A/AC:L/PR:N/UI:N/S:U/C:L/I:N/A:N"
}
],
"remediations": [
{
"category": "vendor_fix",
"details": "BIOTRONIK reports they will not be issuing a product security update; however, BIOTRONIK has identified compensating controls which have been put place that reduce the risk of exploitation and prevent patient safety risks. BIOTRONIK assessed these vulnerabilities and determined no new potential safety risks exist.\nBIOTRONIK recommends users take the following defensive measures to minimize the risk of exploitation of these vulnerabilities. Specifically, users should:",
"product_ids": [
"CSAFPID-0001",
"CSAFPID-0002"
]
}
],
"scores": [
{
"cvss_v3": {
"baseScore": 4.3,
"baseSeverity": "MEDIUM",
"vectorString": "CVSS:3.0/AV:A/AC:L/PR:N/UI:N/S:U/C:L/I:N/A:N",
"version": "3.0"
},
"products": [
"CSAFPID-0001",
"CSAFPID-0002"
]
}
]
},
{
"cve": "CVE-2019-18254",
"cwe": {
"id": "CWE-311",
"name": "Missing Encryption of Sensitive Data"
},
"notes": [
{
"category": "summary",
"text": "The affected products do not encrypt sensitive information while at rest. An attacker with physical access to the CardioMessenger can disclose medical measurement data and the serial number from the implanted cardiac device the CardioMessenger is paired with.CVE-2019-18254 has been assigned to this vulnerability. A CVSS v3 base score of 4.6 has been calculated; the CVSS vector string is (AV:P/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N).",
"title": "Vulnerability Summary"
}
],
"product_status": {
"known_affected": [
"CSAFPID-0001",
"CSAFPID-0002"
]
},
"references": [
{
"category": "external",
"summary": "web.nvd.nist.gov",
"url": "http://web.nvd.nist.gov/view/vuln/detail?vulnId=CVE-2019-18254"
},
{
"category": "external",
"summary": "www.first.org",
"url": "https://www.first.org/cvss/calculator/3.0#CVSS:3.0/AV:P/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N"
}
],
"remediations": [
{
"category": "vendor_fix",
"details": "BIOTRONIK reports they will not be issuing a product security update; however, BIOTRONIK has identified compensating controls which have been put place that reduce the risk of exploitation and prevent patient safety risks. BIOTRONIK assessed these vulnerabilities and determined no new potential safety risks exist.\nBIOTRONIK recommends users take the following defensive measures to minimize the risk of exploitation of these vulnerabilities. Specifically, users should:",
"product_ids": [
"CSAFPID-0001",
"CSAFPID-0002"
]
}
],
"scores": [
{
"cvss_v3": {
"baseScore": 4.6,
"baseSeverity": "MEDIUM",
"vectorString": "CVSS:3.0/AV:P/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N",
"version": "3.0"
},
"products": [
"CSAFPID-0001",
"CSAFPID-0002"
]
}
]
},
{
"cve": "CVE-2019-18256",
"cwe": {
"id": "CWE-257",
"name": "Storing Passwords in a Recoverable Format"
},
"notes": [
{
"category": "summary",
"text": "The affected products use individual per-device credentials that are stored in a recoverable format. An attacker with physical access to the CardioMessenger can use these credentials for network authentication and decryption of local data in transit.CVE-2019-18256 has been assigned to this vulnerability. A CVSS v3 base score of 4.6 has been calculated; the CVSS vector string is (AV:P/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N).",
"title": "Vulnerability Summary"
}
],
"product_status": {
"known_affected": [
"CSAFPID-0001",
"CSAFPID-0002"
]
},
"references": [
{
"category": "external",
"summary": "web.nvd.nist.gov",
"url": "http://web.nvd.nist.gov/view/vuln/detail?vulnId=CVE-2019-18256"
},
{
"category": "external",
"summary": "www.first.org",
"url": "https://www.first.org/cvss/calculator/3.0#CVSS:3.0/AV:P/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N"
}
],
"remediations": [
{
"category": "vendor_fix",
"details": "BIOTRONIK reports they will not be issuing a product security update; however, BIOTRONIK has identified compensating controls which have been put place that reduce the risk of exploitation and prevent patient safety risks. BIOTRONIK assessed these vulnerabilities and determined no new potential safety risks exist.\nBIOTRONIK recommends users take the following defensive measures to minimize the risk of exploitation of these vulnerabilities. Specifically, users should:",
"product_ids": [
"CSAFPID-0001",
"CSAFPID-0002"
]
}
],
"scores": [
{
"cvss_v3": {
"baseScore": 4.6,
"baseSeverity": "MEDIUM",
"vectorString": "CVSS:3.0/AV:P/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N",
"version": "3.0"
},
"products": [
"CSAFPID-0001",
"CSAFPID-0002"
]
}
]
}
]
}
Loading…
Loading…
Sightings
| Author | Source | Type | Date |
|---|
Nomenclature
- Seen: The vulnerability was mentioned, discussed, or observed by the user.
- Confirmed: The vulnerability has been validated from an analyst's perspective.
- Published Proof of Concept: A public proof of concept is available for this vulnerability.
- Exploited: The vulnerability was observed as exploited by the user who reported the sighting.
- Patched: The vulnerability was observed as successfully patched by the user who reported the sighting.
- Not exploited: The vulnerability was not observed as exploited by the user who reported the sighting.
- Not confirmed: The user expressed doubt about the validity of the vulnerability.
- Not patched: The vulnerability was not observed as successfully patched by the user who reported the sighting.
Loading…
Loading…